About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
RAPT Therapeutics image

RAPT Therapeutics

Rank#5396
Market Cap1.68B
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Historyarrow

Rapt was co-founded by four Serial entrepreneurs Brian Halak, Erez Chimovitz, Oren Fuerst, and Noga Alon who sought to combine their experience ranging from cancer focused start-ups to big pharma drug development to create a better future for people fighting cancer. As part of their mission, the team set out to develop technologies that reimagine what cancer therapy can look like.

Missionarrow
Our mission is to develop and commercialize breakthrough immuno-oncology agents for the treatment of patients with cancer, with the goal of improving the lives of patients and their caregivers.
Visionarrow
Our vision is to be a global leader in the development of novel and innovative immuno-oncology therapies by leveraging our deep understanding of the immune system.
Referencesarrow

https://in.investing.com/equities/rapt-therapeutics-inc

https://www.comparably.com/companies/rapt

https://www.crunchbase.com/organization/flx-bio

https://finance.yahoo.com/quote/RAPT/

https://www.rapt.com

https://sec.report/CIK/0001673772

Share

Leadership team
D
Dr. Brian Russell Wong M.D., Ph.D. (CEO, Pres & Director)
M
Mr. Rodney K. B. Young (CFO, Principal Accounting Officer & Sec.)
D
Dr. William Ho (Chief Medical Officer)
Products / Services
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Number of Employees
50 - 100
Address
South San Francisco, California, United States
Established
2015-01-01
Company Registration
SEC CIK number: 0001673772
Revenue
2M - 5M
Traded as
RAPT
Website
https://www.rapt.com
Social Media
linkedin
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo